Difference between revisions of "Non-pegylated liposomal doxorubicin (Myocet)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
m |
||
| Line 4: | Line 4: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Breast cancer]] | *[[Breast cancer]] | ||
| + | |||
| + | ==History of changes in EMA indication== | ||
| + | *4/12/2000: Myocet liposomal, in combination with cyclophosphamide, is indicated for the first-line treatment of metastatic [[breast cancer]] in adult women. | ||
==Also known as== | ==Also known as== | ||
Revision as of 00:40, 11 May 2021
General information
Class/mechanism: A formulation of the citrate salt of the antineoplastic anthracycline antibiotic doxorubicin, encapsulated within liposomes, with antitumor activity.
Diseases for which it is used
History of changes in EMA indication
- 4/12/2000: Myocet liposomal, in combination with cyclophosphamide, is indicated for the first-line treatment of metastatic breast cancer in adult women.
Also known as
- Generic names: liposome-encapsulated doxorubicin citrate, NPLD
- Brand name: Myocet